Work Here?
Overview
Galatea Bio builds diverse genomic data to power precision health. Its offerings include GB Community for diverse biobanking (starting with the Biobank of the Americas), GB Discovery to develop algorithms and pharmaceutical targets from the data, and GB Health to run a clinical lab delivering actionable results to clinics and pharma partners. The company collects DNA data from underrepresented populations, analyzes it to find genetic associations, and translates findings into drug targets and clinical tests. Its goal is to reduce health disparities by broadening genomic datasets and speeding up drug target discovery and actionable genomic results for partners.
About Galatea Bio
Industries
Data & Analytics
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Early VC
Total Funding
$42M
Headquarters
Hialeah, Florida
Founded
2020
Get referred to Galatea Bio
See people who can refer or advise you
Simplify's Take
What believers are saying
- Galatea closed a $25 million round in March 2025 for global biobank expansion.
- The April 2025 iHope deal broadened free testing access and community visibility.
- June 2025 Fabric and DNAnexus collaborations expand clinical distribution and product credibility.
What critics are saying
- FDA has not approved StrataRisk; reimbursement and adoption depend on LDT acceptance.
- GeneDx-backed Fabric can renegotiate or absorb the collaboration, commoditizing Galatea's software.
- A flat 2025-2026 funding market threatens the 10-million-person biobank buildout and cash runway.
What makes Galatea Bio unique
- Galatea Bio combines CLIA-CAP clinical sequencing, biobank data, and ancestry-adjusted PRS.
- Its StrataRisk SaaS targets underrepresented populations with individual-level risk calibration.
- Fabric Genomics partnership bundles rare-variant interpretation and polygenic scoring in one workflow.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$42M
Above
Industry Average
Funded Over
3 Rounds
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Stock Options
401(k) Company Match
Remote Work Options
Performance Bonus
Growth & Insights and Company News
6 month growth
↓ -3%1 year growth
↓ -3%2 year growth
↑ 0%CEI Ventures, Inc., a community development venture capital firm, participated in a $25 million funding round for Galatea Bio, a Miami-based biotechnology company. The funding will support the expansion of Galatea's Global Biobank, which focuses on non-European populations to enhance biomarker discovery and personalized medicine. This initiative aims to improve healthcare access and create jobs in Miami.
Galatea Bio, a Miami, FL-based AI-driven genomic research and clinical genetic testing company, raised $25M in funding
NEW YORK - Genomic data analytics firm Galatea Bio said Thursday that it has raised $25 million in a private financing round.
Galatea Bio launches StrataRisk(TM) Polygenic Risk Score to Scale common disease risk assessment and reporting at the 2025 ACMG Conference.
Galatea Bio has secured $25 million to map the genetic diversity of 10 million people. This initiative aims to assist pharmaceutical companies in developing new medicines.
There are no jobs for Galatea Bio right now.
Find jobs on Simplify and start your career today
About Galatea Bio
Industries
Data & Analytics
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Early VC
Total Funding
$42M
Headquarters
Hialeah, Florida
Founded
2020
There are no jobs for Galatea Bio right now.
Find jobs on Simplify and start your career today